Research & Development

Alchemab, MDC receive grant to develop Huntington’s disease therapy

Biotechnology company Alchemab Therapeutics and Medicines Discovery Catapult (MDC) have received $2.06m (£1.7m) grant from Innovate UK to accelerate the development of disease modifying therapy to treat Huntington’s disease.

Gilgamesh raises funds to advance treatments for mental health

Biotechnology company Gilgamesh Pharmaceuticals has raised $39m in Series B financing round, led by Prime Movers Lab, for advancing treatments for mental health.

Innovent and LG Chem sign agreement for gout disease therapy Tigulixostat

Innovent Biologics and LG Chem Life Sciences have signed an agreement for the latter’s late-stage novel non-purine xanthine oxidase inhibitor (XOI) Tigulixostat for the chronic management of hyperuricemia in individuals with gout disease.

Merck initiates cash tender offer to buy Imago BioSciences

Merck has initiated a cash tender offer, through a subsidiary, to acquire all outstanding shares of common stock of Imago BioSciences.

HitGen, Nitrase partner for library-based drug discovery

Chinese company HitGen has signed a research agreement with biopharmaceutical firm Nitrase Therapeutics to discover DNA-encoded library-based drug.

Rallybio, AbCellera partner to develop therapeutics for rare diseases

US-based biotechnology firm Rallybio has entered into a strategic alliance with AbCellera to discover, develop, and commercialise new antibody-based therapeutics for rare diseases.

iECURE raises funds to advance gene-editing programmes

Gene editing company iECURE has raised $65m in a Series A-1 financing round to advance in vivo programmes to treat rare paediatric liver diseases.

Harbour BioMed, Moderna partner on immunotherapies development

Harbour BioMed’s wholly owned subsidiary Nona Biosciences and global biotechnology firm ModernaTX have entered into a license and collaboration deal for the development of immunotherapies.

Navrogen signs agreement with US NCI for NAV-001 development

Navrogen has signed a cooperative research and development agreement (CRADA) with the US National Cancer Institute (NCI) researchers for the clinical development of NAV-001.